Regresar

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine

Abstract:

Extension of the interval between vaccine doses for the BNT162b2 mRNA vaccine was introduced in the United Kingdom to accelerate population coverage with a single dose. At this time, trial data were lacking, and we addressed this in a study of United Kingdom healthcare workers. The first vaccine dose induced protection from infection from the circulating alpha (B.1.1.7) variant over several weeks. In a substudy of 589 individuals, we show that this single dose induces severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibody (NAb) responses and a sustained B and T cell response to the spike protein. NAb levels were higher after the extended dosing interval (6–14 weeks) compared with the conventional 3- to 4-week regimen, accompanied by enrichment of CD4+ T cells expressing interleukin-2 (IL-2). Prior SARS-CoV-2 infection amplified and accelerated the response. These data on dynamic cellular and humoral responses indicate that extension of the dosing interval is an effective immunogenic protocol.

Año de publicación:

2021

Keywords:

  • B cell
  • variants of concern
  • Neutralization
  • antibody
  • SARS-COV-2
  • dosing interval
  • Vaccine
  • covid-19
  • BNT162b2
  • T cell

Fuente:

scopusscopus

Tipo de documento:

Article

Estado:

Acceso abierto

Áreas de conocimiento:

  • Inmunología
  • Inmunología

Áreas temáticas:

  • Farmacología y terapéutica
  • Medicina y salud
  • Enfermedades

Contribuidores:

Hargreaves A.Hargreaves A.
Whitham R.Whitham R.
Conlon C.P.Conlon C.P.
Altmann T.Altmann T.
Alhussni A.Alhussni A.
Meardon N.Meardon N.
Chinnakannan S.Chinnakannan S.
Tyerman J.K.Tyerman J.K.
Chand M.Chand M.
Denly L.Denly L.
Phillips E.Phillips E.
Akther H.D.Akther H.D.
Donnison T.Donnison T.
Fairman A.Fairman A.
Horner E.Horner E.
Shields A.Shields A.
Drake T.M.Drake T.M.
Turtle L.Turtle L.
Chalk J.Chalk J.
Moore S.C.Moore S.C.
Haworth J.Haworth J.
Barnes E.Barnes E.
Tipton T.Tipton T.
Kilby J.A.Kilby J.A.
Supasa P.Supasa P.
Goulder P.Goulder P.
Sandhar G.Sandhar G.
Hambleton S.Hambleton S.
Diffey B.Diffey B.
Nicols A.R.Nicols A.R.
Duncan C.J.A.Duncan C.J.A.
Abuelgasim H.Abuelgasim H.
Saei A.Saei A.
Hornsby H.Hornsby H.
Eyre D.W.Eyre D.W.
Dold C.Dold C.
Amini A.Amini A.
Linder A.Linder A.
de Silva T.I.de Silva T.I.
Foulkes S.Foulkes S.
Javier Gilbert JaramilloJavier Gilbert Jaramillo
Kasanyinga M.Kasanyinga M.
Hackstein C.P.Hackstein C.P.
Rowland-Jones S.L.Rowland-Jones S.L.
Dimitriadis S.Dimitriadis S.
Jones C.Jones C.
Austin J.A.Austin J.A.
Ali M.Ali M.
Adele S.Adele S.
Brown H.Brown H.
Carroll M.W.Carroll M.W.
Angyal A.Angyal A.
Matthews P.C.Matthews P.C.
Dunachie S.J.Dunachie S.J.
Brown A.Brown A.
Kirk R.Kirk R.
Kelly S.Kelly S.
Brown R.Brown R.
Richter A.Richter A.
Al-Taei S.Al-Taei S.
de Lara C.de Lara C.
Deeks A.S.Deeks A.S.
Arancibia-Cárcamo C.V.Arancibia-Cárcamo C.V.
Skelly D.T.Skelly D.T.
Mongkolsapaya J.Mongkolsapaya J.
Frater J.Frater J.
Chawla A.Chawla A.
Bridges-Webb A.Bridges-Webb A.
Hering L.M.Hering L.M.
Knight M.L.Knight M.L.
Reyes L.S.Reyes L.S.
Haniffa M.Haniffa M.
Longet S.Longet S.
Wootton D.G.Wootton D.G.
Cutteridge J.Cutteridge J.
Jämsén A.Jämsén A.
Hall V.Hall V.
Klenerman P.Klenerman P.
Gillson N.Gillson N.
Hopkins S.Hopkins S.
Lawrie A.Lawrie A.
Johnson S.A.Johnson S.A.
Payne R.P.Payne R.P.
Dejnirattisai W.Dejnirattisai W.
Jeffery K.Jeffery K.
Lee L.Lee L.
Faustini S.Faustini S.
Dobson S.L.Dobson S.L.
Stafford L.Stafford L.
Cross A.Cross A.
Dupont M.Dupont M.
Bayley M.Bayley M.
Malone T.Malone T.
Adlou S.Adlou S.
Screaton G.R.Screaton G.R.
Holmes J.Holmes J.
Azim Ansari M.Azim Ansari M.
Gardiner S.Gardiner S.
Pollard A.J.Pollard A.J.
Adland E.Adland E.